Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing
Innovative Platforms For Improved Viral Vector Development And Scale-Up
Enhancing Titres of Therapeutic Viral Vectors using the Transgene Repression in Vector Production TRiP System
Advancing Gene Therapy Development with a Multi Type AAV Affinity Resin
Achieving rAAV Bioreactor Titer of 1E15 vgL With Novel Plasmid Transient Transfection Platform
Significant Improvements In Total Lentiviral Titer And Quality Seen By Implementing Process C, A Perfusion-Based System
Time‐Dependent Sorption Behavior of Lentiviral Vectors During Anion‐Exchange Chromatography
